Expression and characterization of a codon-optimized blood coagulation factor VIII.

Essentials Recombinant factor VIII (FVIII) is known to be expressed at a low level in cell culture. To increase expression, we used codon-optimization of a B-domain deleted FVIII (BDD-FVIII). This resulted in 7-fold increase of the expression level in cell culture. The biochemical properties of codon-optimized BDD-FVIII were similar to the wild-type protein. SUMMARY: Background Production of recombinant factor VIII (FVIII) is challenging because of its low expression. It was previously shown that codon-optimization of a B-domain-deleted FVIII (BDD-FVIII) cDNA resulted in increased protein expression. However, it is well recognized that synonymous mutations may affect the protein structure and function. Objectives To compare biochemical properties of a BDD-FVIII variants expressed from codon-optimized and wild-type cDNAs (CO and WT, respectively). Methods Each variant of the BDD-FVIII was expressed in several independent Chinese hamster ovary (CHO) cell lines, generated using a lentiviral platform. The proteins were purified by two-step affinity chromatography and analyzed in parallel by PAGE-western blot, mass spectrometry, circular dichroism, surface plasmon resonance, and chromogenic, clotting and thrombin generation assays. Results and conclusion The average yield of the CO was 7-fold higher than WT, whereas both proteins were identical in the amino acid sequences (99% coverage) and very similar in patterns of the molecular fragments (before and after thrombin cleavage), glycosylation and tyrosine sulfation, secondary structures and binding to von Willebrand factor and to a fragment of the low-density lipoprotein receptor-related protein 1. The CO preparations had on average 1.5-fold higher FVIII specific activity (activity normalized to protein mass) than WT preparations, which was attributed to better preservation of the CO structure as a result of considerably higher protein concentrations during the production. We concluded that the codon-optimization of the BDD-FVIII resulted in significant increase of its expression and did not affect the structure-function properties.

Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.

INTRODUCTION: The thrombin generation test (TGT) is used both as a global haemostasis assay, and to compare activities of coagulation factor concentrates that have been spiked into patient plasma. However, TGT has not been systematically optimized to evaluate factor VIII (FVIII) product potency. AIMS: To improve the sensitivity of TGT to FVIII and allow a comparative analysis of the thrombin generating capacities of FVIII concentrates against reference preparations with known FVIII activity. METHODS: Concentrations of TGT components (analytical variables) were assessed to maximize the linearity and range of responses to the concentration of FVIII. RESULTS: We optimized the range and sensitivity of the TGT assay with respect to FVIII through the addition of FXIa to the assay. Other parameters that were adjusted, i.e. tissue factor (TF), procoagulant lipids and plasma concentrations, did not improve the ability of the assay to measure both high and very low levels of FVIII. In the optimized TF/FXIa-activated TGT assay, all thrombin generation curve parameters were suitable for FVIII quantification, but thrombin peak height and maximal velocity demonstrated better linearity in the desired FVIII range. We found that the optimized TF/FXIa-activated TGT has a wider range of sensitivity to FVIII than a commercially available TGT. Additionally, we demonstrated that the TF/FXIa-activated assay performs adequately by comparing potency measurements of five commercially available FVIII products using TGT and traditional chromogenic and one-stage clotting assays. CONCLUSIONS: The optimized TGT assay can be used to quantify and compare the thrombin generating capacities of FVIII concentrates.

Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter.

Several studies have demonstrated that dihydropyrimidine dehydrogenase (EC 1.3.1.2) has a critical role in the pharmacokinetics of the anticancer agent 5-fluorouracil. We previously reported the structural organization of the human DPYD gene. In this article, we describe the molecular cloning and functional characterization of 1.2 kb of the 5' flanking region of the DPYD gene. Sequence analysis demonstrated that this region of the DPYD gene lacks the typical TATA or CCAAT boxes with several GC-rich regions containing potential cis-regulatory elements. Progressive 5' deletions of the 5' flanking region were fused to the luciferase reporter gene and transient expression measured following transfection into HeLa and 293 cells. Comparative analysis of luciferase activity revealed that a 208 bp region of the DPYD gene (-121/+86) contained equivalent transcriptional activity to the complete 1.2 kb 5' flanking region of the DPYD gene. Site-directed mutagenesis of the luciferase reporter constructs demonstrated that the -72/-23 sequence contained two regulatory regions (designated elements I and II) essential for promoter activity. Gel shift experiments demonstrated that both regulatory elements specifically bind with protein(s) from nuclear extracts of 293 cells. Competitive binding experiments with 293 nuclear extracts and radiolabeled oligonucleotides (corresponding to elements I and II) suggest that the same protein(s) bind to both regulatory elements. We conclude that constitutive expression of the DPYD gene involves a limited GC-rich region of the 5' flanking sequence of the DPYD gene which contains two regulatory elements.

The transposon A(R)4-24P[white, rosy] in Drosophila melanogaster is subject to position-effect variegation at a non-centromeric insertion site.

The white gene within the transposon A(R)4-24P[white,rosy] inserted at cytological location 24D1-2 in the euchromatic portion of the Drosophila melanogaster genome exhibits a mosaic pattern of expression which is modified by temperature and Y-chromosome number, as in cases of classical position-effect variegation (PEV). The eye colour of the flies in this variegated stock remains mosaic in the presence of the PEV modifier Su(var)3-6, slightly less so with Su(var)3-9 and Su(var)2-5, and full suppression of variegation occurs in the presence of Su(var)3-7. We have induced further transposition of A(R)4-24 and isolated two mosaic stocks with this transgene at new cytological locations. In these stocks, the A(R)4-24 transposon was flanked by the same genomic DNA fragments as in the original location. Spontaneous loss of these fragments leads to reversion of the variegated eye colour to wild-type. We suggest that the flanking DNA fragments from 24D1-2 are capable of inducing position-effect variegation without any association with centromeric heterochromatin. In situ hybridisation and Southern analysis demonstrate that the 5' flanking genomic fragment contains repeated sequences which are abundantly present in heterochromatin.

[Position effect variegation of the mosaic type, arising as a result of transposition AR4-24P[white, rosy] in the Drosophila melanogaster genome]. / Effekt polozheniia mozaichnogo tipa, voznikaiushchii vsledstvie peremeshcheniia transpozona AR4-24P[white, rosy] v genome Drosophila melanogaster]

A line with the mosaic expression of the white+ transgene was obtained by inducing transposition of the AR4-24P[white, rosy] transposon and was used for the second round of induction. As a result, 57 lines with the mosaic eye pigmentation were obtained. In situ hybridization and Southern blotting showed that genomic DNA fragments flanking AR4-24 were, in some cases, transposed together with the transposon. A spontaneous loss of these fragments resulted in reversion to the wild-type phenotype. The mosaic eye pigmentation in a line that carried the AR4-24 transposon flanked with the same fragments in region 24D1-2 was not affected by the Su(var)3-6 gene modifying position effect variegation (PEV). Other PEV modifiers, Su(var)3-9 and Su(var)2-5, had only a slight effect on PEV; Su(var)3-7 restored the wild-type phenotype. The genomic fragments captured by the transposon may contain DNA sequences that autonomously induce mosaic PEV of the white gene.

[Comparison of the molecular and genetic map of the 2B6-2B7-8 of Drosophila melanogaster X-chromosome]. / Sopostavlenie molekuliarnoi i geneticheskoi kart raiona 2B6-2B7-8 X-khromosomy Drosophila melanogaster.

Molecular and genetic data were compared for the 2B6-2B7-8 region of the Drosophila melanogaster X chromosome. This region contains the dor (deep orange) and swi (single wing) genes influencing ecdysterone-dependent gene expression. Genes which had not been identified previously by genetic methods were shown to be present in this region. Two novel loci, designated a6 and b6, were characterized in detail. Both genes are expressed throughout Drosophila embryogenesis. The product of b6 has a homology with mammalian pentraxins. This is the first Drosophila gene found to contain the pentraxin motif.

[Microcloning and characteristics of DNA from regions of the centromeric heterochromatin of Drosophila melanogaster polytene chromosomes]. / Mikroklonirovanie i kharakteristika DNK iz raionov pritsentromernogo geterokhromatina politennykh khromosom Drosophila melanogaster.

A method of microcloning, which involves microsurgical excision of chromosome fragments, DNA amplification by means of a polymerase chain reaction (PCR), and ligation of amplified products with plasmids, was employed in studying Drosophila polytene chromosomes for the first time. Clones of the DNA library thus obtained contained inserts varying in size from 0.1 to 0.5 kb. DNA sequencing of five clones of the library showed that pericentromeric heterochromatin contained the 17.6 and 297 retrotransposons, the ninja retrotransposon characteristic of D. simulans, and two Drosophila repetitive elements, a8 and a12, the function of which remains unknown.

Molecular characterization of the deep orange (dor) gene of Drosophila melanogaster.

Mutations of the dor gene of Drosophila melanogaster cause defects in different stages of development. Heterozygotes for lethal or viable dor alleles and the rearrangement T(1;2)dor(var7), which causes position effect variegation of dor, exhibit traits such as rough eyes, reduction of bristles on the thorax and scutellum and wavy wings. The dor gene was mapped to the proximal part of the 2B3-5 band or in the interband between 2B3-5 and 2B6 and localised within an interval of 5 kb on the physical map of the cloned 2B region. The 3.0-3.1 kb dor transcript was detected by Northern hybridization at all stages of development and is expressed in salivary glands of third instar larve. This RNA was not expressed in the dor mutants with insertions in the 5' part of the gene. The sequence of the 3180 bp (dor cDNA predicts a 115.3 kDa protein that contains a cysteine- and histidine-rich zinc finger-like motif CX2CX13CXHX2HX2CX2H at the C-terminus. The protein sequence reveals 23% identity to the Saccharomyces cerevisiae PEP3 protein. The most significant homology (57%) similarity and 32%, identity) between the DOR and PEP3 proteins is observed at the C-termini of the proteins.